Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline plc : Director/PDMR Shareholding

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2012 | 08:11pm CET

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of a Person Discharging Managerial Responsibility in the Ordinary Shares of GlaxoSmithKline plc ("Ordinary Shares") on 2 May 2012:

Mr S M Bicknell

Transfer of 250 Ordinary Shares into an ISA at £14.3225 per share.



The Company and the above mentioned person was advised of this transaction on 3 May 2012.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

3 May 2012


This information is provided by RNS
The company news service from the London Stock Exchange
ENDRDSQXLFBLEFXBBD
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
02/20GLAXOSMITHKLINE PLC : Today’s Research Reports on Trending Tickers: GlaxoSmithKl..
AC
02/16GLAXOSMITHKLINE : GSK submits landmark IMPACT data to European Medicines Agency ..
AQ
02/15GLAXOSMITHKLINE : Details Findings in Organic Research [High-Throughput Automate..
AQ
02/15GLAXOSMITHKLINE : An Application for the Trademark "ELEBRATO" Has Been Filed by ..
AQ
02/15FINDINGS FROM GLAXOSMITHKLINE PLC IN : Efficacy,...
AQ
02/15GLAXOSMITHKLINE : Reports from GlaxoSmithKline plc Provide New Insights into Bio..
AQ
02/15GLAXOSMITHKLINE : Investigators at GlaxoSmithKline plc Release New Data on Monoc..
AQ
02/15GLAXOSMITHKLINE : New Whooping Cough Study Results from GlaxoSmithKline plc Desc..
AQ
02/15GLAXOSMITHKLINE : GSK receives European approval for expanded indication for Flu..
PU
02/14GLOBAL EYE CANCER MARKET REPORT WITH : Global Eye Cancer Market - Global Industr..
AQ
More news
News from SeekingAlpha
02/20FDA tentatively OKs Mylan's HIV combo pill 
02/20AGENUS : Positioned To Rapidly Enhance Shareholder Value 
02/16WALL STREET BREAKFAST : Major Recovery For Wall Street 
02/16'Intense' flu season to continue 
02/15YOUR DAILY PHARMA SCOOP : Achaogen Update, Catabasis' Positive Results, Bristol-.. 
Financials ( GBP)
Sales 2018 30 206 M
EBIT 2018 8 317 M
Net income 2018 4 101 M
Debt 2018 13 333 M
Yield 2018 6,04%
P/E ratio 2018 15,35
P/E ratio 2019 13,94
EV / Sales 2018 2,62x
EV / Sales 2019 2,53x
Capitalization 65 696 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 15,3  GBP
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-1.67%91 862
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%224 785
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 160
MERCK AND COMPANY-0.50%153 359